Merck Halts Second PAH Drug Study Early on Strong Efficacy Results

Merck (MRK) has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the disease.This decision is based on strong efficacy data from previously conducted studies on Winrevair. Per Meck, an external steering committee unanimously concluded that the HYPERION study has lost ‘clinical equipoise’.How Does Losing Clinical Equipoise Benefit Merck?Clinical equipoise refers to a genuine uncert ...